LFCR Q3 2025 Earnings Call Summary

Revenue: $31.1 million for Q3 2025, up 26% from $24.7 million in Q3 2024.
Gross Profit: Increased to $7.8 million from $5.4 million year-over-year.
Net Loss: Reported at $10 million, or $0.29 per diluted share, improved from a loss of $16.2 million ($0.53 per diluted share) in the prior year.
Adjusted EBITDA: $3.1 million, a significant increase from a negative $1.8 million in Q3 2024.
SG&A Expenses: Reduced to $8.9 million from $14.8 million, reflecting a decrease in both recurring and nonrecurring expenses.

Lifecore is positioned as a differentiated injectable CDMO, focusing on high-grade hyaluronic acid.
Achieved key milestones in expanding commercial business and advancing a late-stage pipeline of 11 programs expected to launch between 2026 and 2029.
Successful FDA inspection in March and positive results from five customer audits during the quarter.
Signed two new customer contracts in Q3 and two additional contracts post-quarter, including a significant commercial site transfer from a large pharmaceutical company.
Continued emphasis on operational excellence and cost control, with a 20% reduction in workforce over 18 months leading to improved productivity.

For the transition period from May 26 to December 31, 2025, Lifecore expects:
- Revenue between $74 million to $76 million.
- Net loss ranging from $18.4 million to $16.4 million.
- Adjusted EBITDA between $12 million to $14 million.
Anticipates a stronger second half of calendar year 2026, with revenue split expected to be 45% in the first half and 55% in the second half.

Despite improvements, the company reported a net loss, indicating ongoing financial challenges.
Decline in CDMO gross profit due to lower development revenues and product mix issues.
Continued legacy matters affecting SG&A expenses, although reductions have been significant.
The timeline for the commercial site transfer is projected at 24 to 30 months, which may delay revenue realization from this new contract.

Management indicated that the regionalization of manufacturing is creating new opportunities for CDMOs, with increased interest in commercial site transfers.
Future SG&A reductions may yield an additional $1.5 million in savings per quarter, potentially lowering the run rate to $7.5 million to $8 million.
The company expects to be the sole manufacturer for the new commercial product, which could become a top 5 customer once fully operational.
Management expressed confidence in their growth strategy and operational improvements, positioning Lifecore for sustained profitability moving forward.

LFCR — Lifecore Biomedical, Inc.